Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
Corcept Therapeutics completed enrollment in the phase III ROSELLA study for relacorilant combined with Abraxane for recurrent, platinum-resistant ovarian cancer, expecting progression-free survival data by 2024-end. Relacorilant is also in phase III studies for Cushing’s syndrome and adrenal cancer, with data expected in 2024. Corcept's shares dropped 25.4% this year.
Reference News
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
Corcept Therapeutics completed enrollment in the phase III ROSELLA study for relacorilant combined with Abraxane for recurrent, platinum-resistant ovarian cancer, expecting progression-free survival data by 2024-end. Relacorilant is also in phase III studies for Cushing’s syndrome and adrenal cancer, with data expected in 2024. Corcept's shares dropped 25.4% this year.